Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Colchicine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
In-stent Restenosis
1 trial -
Colla corii asini
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thalassemia
1 trial -
Colquhounia Root Tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatoid Arthritis
1 trial -
Combination Cinacalcet with Vitamin D analogue
Hospital Authority, Hong Kong
Secondary Hyperparathyroidism
1 trial -
Combination of antiplatelet drugs and anticoagulants for at least one month
The First People's Hospital of Lianyungang
Acute Myocardial Infarction
1 trial -
Continuos epidural infusion
Hospital Authority, Hong Kong
Analgesia, Epidural
1 trial -
Conventional therapy + S (+)-Ketamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
S-ketamine
1 trial -
Cook balloon uterine stent
Hospital Authority, Hong Kong
Intrauterine Adhesion
1 trial -
Covid-19 vaccine (0-1-4 schedule)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19 Pneumonia
2 trials -
Cytokine-induced killer cells+ FOLFOX4
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
Dabigatran Etexilate
The First People's Hospital of Lianyungang
Atrial Fibrillation
1 trial -
Danlou Tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease(CAD)
1 trial -
Dapagliflozin 10 MG
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
Daphnetin
The First People's Hospital of Lianyungang
Lower Extremity Lymphedema
1 trial -
Daratumumab and corticosteroid treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acquired Hemophilia
1 trial -
De-escalated Dual Antiplatelet Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
DePuy ASR Hip System
International Peace Maternity and Child Health Hospital
Rheumatoid Arthritis
1 trial -
Dental foam "Biorepair PERIBIOMA"
The First People's Hospital of Lianyungang
Oral Health
1 trial -
Desmopressin
The First People's Hospital of Lianyungang
Patients Undergoing Endoscopic Sinus Surgery
1 trial -
Dex-Esk
The First People's Hospital of Lianyungang
Older Patients
1 trial -
Dexamethasone
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
Dexamethasone
The First People's Hospital of Lianyungang
Carcinoma, Non-Small-Cell Lung
1 trial -
Dexamethasone and N-acetylcysteine (NAC)
Hospital Authority, Hong Kong
Carbon Monoxide Poisoning
1 trial -
Dexamethasone and N-acetylcysteine (NAC)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carbon Monoxide Poisoning
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources